Literature DB >> 16569849

Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.

Mark N Prichard1, Kathy A Keith, Debra C Quenelle, Earl R Kern.   

Abstract

N-Methanocarbathymidine [(N)-MCT] is a conformationally locked nucleoside analog that is active against some herpesviruses and orthopoxviruses in vitro. The antiviral activity of this molecule is dependent on the type I thymidine kinase (TK) in herpes simplex virus and also appears to be dependent on the type II TK expressed by cowpox and vaccinia viruses, suggesting that it is a substrate for both of these divergent forms of the enzyme. The drug is also a good inhibitor of viral DNA synthesis in both viruses and is consistent with inhibition of the viral DNA polymerase once it is activated by the viral TK homologs. This mechanism of action explains the rather unusual spectrum of activity, which is limited to orthopoxviruses, alphaherpesviruses, and Epstein-Barr virus, since these viruses express molecules with TK activity that can phosphorylate and thus activate the drug. The compound is also effective in vivo and reduces the mortality of mice infected with orthopoxviruses, as well as those infected with herpes simplex virus type 1 when treatment is initiated 24 h after infection. These results indicate that (N)-MCT is active in vitro and in vivo, and its mechanism of action suggests that the molecule may be an effective therapeutic for orthopoxvirus and herpesvirus infections, thus warranting further development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569849      PMCID: PMC1426929          DOI: 10.1128/AAC.50.4.1336-1341.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  41 in total

Review 1.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

2.  A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase.

Authors:  M E Black; D E Hruby
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

3.  Mapping and identification of the vaccinia virus thymidine kinase gene.

Authors:  D E Hruby; L A Ball
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

Review 4.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections.

Authors:  R J Rybak; C B Hartline; Y L Qiu; J Zemlicka; E Harden; G Marshall; J P Sommadossi; E R Kern
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 6.  Mechanism of action and selectivity of acyclovir.

Authors:  G B Elion
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

7.  Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus.

Authors:  K K Biron; J A Fyfe; J E Noblin; G B Elion
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

8.  A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Authors:  V Sullivan; C L Talarico; S C Stanat; M Davis; D M Coen; K K Biron
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

9.  Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir.

Authors:  E Littler; A D Stuart; M S Chee
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

10.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Authors:  A K Field; M E Davies; C DeWitt; H C Perry; R Liou; J Germershausen; J D Karkas; W T Ashton; D B Johnston; R L Tolman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

View more
  29 in total

1.  A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus.

Authors:  Mark N Prichard; Shannon L Daily; Geraldine M Jefferson; Amie L Perry; Earl R Kern
Journal:  J Virol Methods       Date:  2007-05-30       Impact factor: 2.014

2.  Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.

Authors:  Rachel B Gill; Scott H James; Mark N Prichard
Journal:  J Gen Virol       Date:  2012-05-02       Impact factor: 3.891

3.  A greener enantioselective synthesis of the antiviral agent North-methanocarbathymidine (N-MCT) from 2-deoxy-d-ribose.

Authors:  Olaf R Ludek; Victor E Marquez
Journal:  Tetrahedron       Date:  2009-10-10       Impact factor: 2.457

4.  Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Ravinder Earla; Suman Sirimulla; Jake Brain Bailey; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2013-05-09       Impact factor: 4.200

5.  A nucleotide-analogue-induced gain of function corrects the error-prone nature of human DNA polymerase iota.

Authors:  Amit Ketkar; Maroof K Zafar; Surajit Banerjee; Victor E Marquez; Martin Egli; Robert L Eoff
Journal:  J Am Chem Soc       Date:  2012-06-14       Impact factor: 15.419

6.  Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.

Authors:  S H James; R J Whitley
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

7.  Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.

Authors:  Mark N Prichard; Kathy A Keith; Mary P Johnson; Emma A Harden; Alexis McBrayer; Ming Luo; Shihong Qiu; Debasish Chattopadhyay; Xuesen Fan; Paul F Torrence; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

8.  Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.

Authors:  Mark N Prichard; Debra C Quenelle; Caroll B Hartline; Emma A Harden; Geraldine Jefferson; Samuel L Frederick; Shannon L Daily; Richard J Whitley; Kamal N Tiwari; Joseph A Maddry; John A Secrist; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

9.  Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.

Authors:  S E Altmann; J C Jones; S Schultz-Cherry; C R Brandt
Journal:  Virology       Date:  2009-04-22       Impact factor: 3.616

10.  Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.

Authors:  Mark N Prichard; John D Williams; Gloria Komazin-Meredith; Atiyya R Khan; Nathan B Price; Geraldine M Jefferson; Emma A Harden; Caroll B Hartline; Norton P Peet; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.